Variant sequences: the new frontier in sequence IP

A variant sequence is typically a naturally-occurring molecule, most frequently protein, which has been modified in order to impart desired characteristics such as improved stability under anticipated use conditions, or increased activity. Optimising sequences and, of course, the associated IP rights, span most areas of biotechnology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

In-house counsel

WATCH: LEO Pharma head of IP rights on doing more with less

7 October 2026 With resources under pressure, the Danish company’s IP leader explains how AI, smarter prioritisation and close business ties can help IP teams boost their impact.

Pharma

Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom

6 October 2026 Day one of the UK patent trial over blockbuster drug Jardiance put a lack of biological data, disputed evidence of testing and the limits of scientific prediction under the spotlight.

Careers

Latham adds ‘exceptional’ ITC expert and 5th trial lawyer in a year

6 October 2026 The new partner advises technology and life sciences companies in Section 337 investigations and related patent disputes, drawing on extensive private practice and government experience.

More features

Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom

What's AI best at? In-house teams are still learning

WATCH: Genevant IP director on tackling UPC-EPO opposition divide

5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?

Lilly loses Fed Circ rehearing bid, sparking enablement questions

Takeda sees off UK challenge to Elvanse SPC

Mylan throws down new gauntlet in Novo Wegovy patent fight

Novartis defeats Orange Book challenge but suffers EU setback

Variant sequences: the new frontier in sequence IP

More on this story

Editor's picks

Editor's picks

More features